2021 Analysis and Review: Nutraceutical Gummies Market by Functionality – Digestive Health, Immunity and Strength, Cardiovascular Health, and Bone and Muscle Health for 2021 – 2031
Dear Ladies & Gentlemen,
Hope all is well, Glad to share details with you of our upcoming conference “6th Biosimilars 2015” taking place on 10th & 11th March 2015, The Kensington Close Hotel, Wrights Lane, London, UK. Please find attached the updated agenda for the same with this email.
In case you and your colleagues would like to book as delegate there is a discounted price now :-
Introductory Offer (3 delegate places for the price of 2):- A huge saving of £ 600
Super Early Discount (Till 26th December 2014):- Conference Delegate Pass (£ 600 + VAT per delegate)
We can also offer some other sponsorship packages which include speaking opportunities/ branding etc. For some sample packages on the same please email me and I can call you to discuss the options further.
For any further assistance please feel free to contact me anytime. I look forward to a positive response from your end.
Best Regards,
Deepak Raj
Delegate and Sponsorship Sales
Virtue Insight
Gsm - + 91 9171350244;
Hemp Based Products Market: Outline
The use of hemp in various products and applications is rising at a great rate over the years. The medicinal benefits of hemp are tremendous and this aspect may bring substantial growth opportunities for the global hemp based products market during the forecast period of 2020-2030.
2021 Analysis and Review: Nutraceutical Gummies Market by Functionality – Digestive Health, Immunity and Strength, Cardiovascular Health, and Bone and Muscle Health for 2021 – 2031
Dear Ladies & Gentlemen,
Hope all is well, Glad to share details with you of our upcoming conference “6th Biosimilars 2015” taking place on 10th & 11th March 2015, The Kensington Close Hotel, Wrights Lane, London, UK. Please find attached the updated agenda for the same with this email.
In case you and your colleagues would like to book as delegate there is a discounted price now :-
Introductory Offer (3 delegate places for the price of 2):- A huge saving of £ 600
Super Early Discount (Till 26th December 2014):- Conference Delegate Pass (£ 600 + VAT per delegate)
We can also offer some other sponsorship packages which include speaking opportunities/ branding etc. For some sample packages on the same please email me and I can call you to discuss the options further.
For any further assistance please feel free to contact me anytime. I look forward to a positive response from your end.
Best Regards,
Deepak Raj
Delegate and Sponsorship Sales
Virtue Insight
Gsm - + 91 9171350244;
Hemp Based Products Market: Outline
The use of hemp in various products and applications is rising at a great rate over the years. The medicinal benefits of hemp are tremendous and this aspect may bring substantial growth opportunities for the global hemp based products market during the forecast period of 2020-2030.
Briefing based on the key findings of my research on the Global Generic Pharmaceuticals Market 2010, covering the developed markets like the U.S, Germany, UK, France, Italy and Spain as well as the emerging markets such as India and China.
Market research for Indian Pharmaceutical Market switching over from prescribed to OTC products. Scope of Indian Pharmaceutical OTC market, opportunities and challenges.
Opportunities & Challenges in West Africa's (Ghana & Nigeria) Healthcare and ...Aiswariya Chidambaram
This presentation made at the Pharma Insights Briefing session of CPhI Worldwide 2014, Paris, provides information on the market opportunities of
the fastest growing pharmaceutical markets in Africa: Ghana and Nigeria.
• Market sizing and Growth Trends
• Key Merger, Acquisition and Partnership Assessment
• Market Drivers and Challenges
• Pharmaceutical Procurement, Supply, Distribution and Retail
• SWOT and PESTLE Analysis
• Competitive Landscape Analysis
• Therapeutic Area Growth Analysis
• Strategic Recommendations
Oncology biosimilars Market Report in PPT: Top Companies, Trends and Future D...IMARC Group
According to the latest report by IMARC Group,the global oncology biosimilars market exhibited strong growth during 2015-2020.
Oncology biosimilars are cost-effective counterparts of the already licensed reference biologics.
Introduction to the pharmaceutical market and practiceWayne Wei
As a lecturer for "Basic Principles of Drug Discovery and Development" for Department of Life Sciences, National Central of University for two years.
In charge of "Introduction to the pharmaceutical market and practice".
Emergpharma`s chinese diabetes pharmaceutical market Jose Ignacio Diaz
Chinese Diabetes Pharmaceutical Market surpassed USD 3 bn in 2012 and is expected to achieve 7bn in 2007. according to Emergpharma's latest report presented yesterday. It is one of the fastest growth segment in the Global Pharmaceutical Market. Novo Nordisk, Bayer and Sanofi dominates this market with more than 50%.
Corporate Strategy Assignment - The Global Pharmaceutical IndustryAmany Hamza
This report provides an analytical strategic review of the global pharmaceutical industry. In the first part, it covers the external environment of the global pharmaceutical industry using PESTEL analysis and outlines the Key drivers for change. It then uses the Five Forces analysis to demonstrate the industry attractiveness. Secondly, we illustrate the strategic capabilities of Novartis using the Value chain. Finally, we attempt to highlights its financial performance, position and culture.
Strategic Analysis of the Indian Pharmaceutical Contract Manufacturing Market...Aiswariya Chidambaram
The Indian Pharmaceutical CMO market has been analyzed and assessed with respect to APIs and finished dose formulations (solids, liquids and injectables). Strategic recommendations for the success of market participants have been provided.
Speakers:
Paul Chipperton, Vice President, Business Development & Marketing, matREGEN
Nina Chagnon, Director of Business Development, MaRS Discovery District
For more information and the webcast link: http://www.marsdd.com/Events/Event-Calendar/BioEntrepreneurship/2007/business-models-12192007.html
Global Biopharmaceutical Contract Manufacturing Market - Qualitative and Quan...Aiswariya Chidambaram
This presentation which highlights the key market and technology trends in the global biopharmaceutical contract manufacturing market was delivered as a lecture at the In-Focus Seminar session at CPhI Worldwide 2013 held at Frankfurt, Germany.
“An Era of Mobile Killer Apps in a transforming Devices Landscape”
KEY SPEAKERS:-
Pradeep Garani, Senior VP, Product Engineering, Reliance Jio Infocomm Limited
Puneet Gupta, Associate VP & Head, Mobile Computing Product Line, Infosys Labs
Sunil Kamath, Vice President for South Asia, Opera Software
Viswanath Poosala, CTO - Subscriber Data Management & Messaging, Alcatel-Lucent & Head, Bell Labs India
Sachidanand Mangala, Program Director, India Software Lab, IBM
Lux Rao, CTO - Technology Services, HP
Pratima Amonkar, Director Audience Marketing - Developer and Platform Evangelism, Microsoft
Balagopal K S, Manager - Developer Program & AppStore(Emerging Markets), Vodafone
Sampath Manickam, Regional Head - Data Centre, Managed Services & Cloud, Nxtra Data Limited, A Subsidiary of Bharti Airtel Limited
Anantharaman P.N, Independent Researcher, Stealth Mode, Former Director Engineering, Adobe Systems
Seenuvasan Amaranathan, Solution Architect Director, Dell
Amit Rohatgi, Senior Product Manager - Personalization and Mobility, Manthan Systems
Uttam Kumar, Head - New Technologies Innovation & Incubation, Aircel
Sunzay Passari, Executive VP – VAS & Devices, Essar Teleholdings & BPL Mobile Communications
Udayan Banerjee, VP, NIIT Technologies
Ravi Vyas, Project Manager, Vserv.mobi
GirishTrivedi, Co-Founder, Director, Monk Consulting
Gaurav Bhalotia, Founder and CEO, BahutBadhiya Labs (Former Director, Flipkart.com)
Ajay Kumar Jha, Head, Device Technology & On Device Applications, Sistema Shyam Teleservices
Plus Many more...
WHO YOU WILL MEET:-
CEO’s, CIO’s, CTO’s, Vp’s, Directors, Brand Managers, Head & Senior Managers, Developers of:
Applications
Mobile Content
Application Stores
Product Development
Mobile Services Innovations
Product Marketing
Digital Strategy
Data Services
Entertainment
Devices
FROM THE FOLLOWING:-
Wireless & Fixed Operators
Content Owners
Platform Owners
OS
Terminal & Platforms Vendors
OEM
ISP & MVNO’s
Handset Manufacturers
Satellite Operators
Content Retailers
Entertainment
Creative Agencies
Social Media
WHY SHOULD YOU ATTEND:-
3rd Annual Mobile Apps 2014 is the place to meet all the key decision makers across the mobile Application eco-system from enterprises, telecom operators, regulators, government agencies, service providers, system integrators, Developers and vendors. This congress will provide great networking opportunities with industry leaders, presenting you with the opportunity to meet and do business with like minded individuals.
Briefing based on the key findings of my research on the Global Generic Pharmaceuticals Market 2010, covering the developed markets like the U.S, Germany, UK, France, Italy and Spain as well as the emerging markets such as India and China.
Market research for Indian Pharmaceutical Market switching over from prescribed to OTC products. Scope of Indian Pharmaceutical OTC market, opportunities and challenges.
Opportunities & Challenges in West Africa's (Ghana & Nigeria) Healthcare and ...Aiswariya Chidambaram
This presentation made at the Pharma Insights Briefing session of CPhI Worldwide 2014, Paris, provides information on the market opportunities of
the fastest growing pharmaceutical markets in Africa: Ghana and Nigeria.
• Market sizing and Growth Trends
• Key Merger, Acquisition and Partnership Assessment
• Market Drivers and Challenges
• Pharmaceutical Procurement, Supply, Distribution and Retail
• SWOT and PESTLE Analysis
• Competitive Landscape Analysis
• Therapeutic Area Growth Analysis
• Strategic Recommendations
Oncology biosimilars Market Report in PPT: Top Companies, Trends and Future D...IMARC Group
According to the latest report by IMARC Group,the global oncology biosimilars market exhibited strong growth during 2015-2020.
Oncology biosimilars are cost-effective counterparts of the already licensed reference biologics.
Introduction to the pharmaceutical market and practiceWayne Wei
As a lecturer for "Basic Principles of Drug Discovery and Development" for Department of Life Sciences, National Central of University for two years.
In charge of "Introduction to the pharmaceutical market and practice".
Emergpharma`s chinese diabetes pharmaceutical market Jose Ignacio Diaz
Chinese Diabetes Pharmaceutical Market surpassed USD 3 bn in 2012 and is expected to achieve 7bn in 2007. according to Emergpharma's latest report presented yesterday. It is one of the fastest growth segment in the Global Pharmaceutical Market. Novo Nordisk, Bayer and Sanofi dominates this market with more than 50%.
Corporate Strategy Assignment - The Global Pharmaceutical IndustryAmany Hamza
This report provides an analytical strategic review of the global pharmaceutical industry. In the first part, it covers the external environment of the global pharmaceutical industry using PESTEL analysis and outlines the Key drivers for change. It then uses the Five Forces analysis to demonstrate the industry attractiveness. Secondly, we illustrate the strategic capabilities of Novartis using the Value chain. Finally, we attempt to highlights its financial performance, position and culture.
Strategic Analysis of the Indian Pharmaceutical Contract Manufacturing Market...Aiswariya Chidambaram
The Indian Pharmaceutical CMO market has been analyzed and assessed with respect to APIs and finished dose formulations (solids, liquids and injectables). Strategic recommendations for the success of market participants have been provided.
Speakers:
Paul Chipperton, Vice President, Business Development & Marketing, matREGEN
Nina Chagnon, Director of Business Development, MaRS Discovery District
For more information and the webcast link: http://www.marsdd.com/Events/Event-Calendar/BioEntrepreneurship/2007/business-models-12192007.html
Global Biopharmaceutical Contract Manufacturing Market - Qualitative and Quan...Aiswariya Chidambaram
This presentation which highlights the key market and technology trends in the global biopharmaceutical contract manufacturing market was delivered as a lecture at the In-Focus Seminar session at CPhI Worldwide 2013 held at Frankfurt, Germany.
“An Era of Mobile Killer Apps in a transforming Devices Landscape”
KEY SPEAKERS:-
Pradeep Garani, Senior VP, Product Engineering, Reliance Jio Infocomm Limited
Puneet Gupta, Associate VP & Head, Mobile Computing Product Line, Infosys Labs
Sunil Kamath, Vice President for South Asia, Opera Software
Viswanath Poosala, CTO - Subscriber Data Management & Messaging, Alcatel-Lucent & Head, Bell Labs India
Sachidanand Mangala, Program Director, India Software Lab, IBM
Lux Rao, CTO - Technology Services, HP
Pratima Amonkar, Director Audience Marketing - Developer and Platform Evangelism, Microsoft
Balagopal K S, Manager - Developer Program & AppStore(Emerging Markets), Vodafone
Sampath Manickam, Regional Head - Data Centre, Managed Services & Cloud, Nxtra Data Limited, A Subsidiary of Bharti Airtel Limited
Anantharaman P.N, Independent Researcher, Stealth Mode, Former Director Engineering, Adobe Systems
Seenuvasan Amaranathan, Solution Architect Director, Dell
Amit Rohatgi, Senior Product Manager - Personalization and Mobility, Manthan Systems
Uttam Kumar, Head - New Technologies Innovation & Incubation, Aircel
Sunzay Passari, Executive VP – VAS & Devices, Essar Teleholdings & BPL Mobile Communications
Udayan Banerjee, VP, NIIT Technologies
Ravi Vyas, Project Manager, Vserv.mobi
GirishTrivedi, Co-Founder, Director, Monk Consulting
Gaurav Bhalotia, Founder and CEO, BahutBadhiya Labs (Former Director, Flipkart.com)
Ajay Kumar Jha, Head, Device Technology & On Device Applications, Sistema Shyam Teleservices
Plus Many more...
WHO YOU WILL MEET:-
CEO’s, CIO’s, CTO’s, Vp’s, Directors, Brand Managers, Head & Senior Managers, Developers of:
Applications
Mobile Content
Application Stores
Product Development
Mobile Services Innovations
Product Marketing
Digital Strategy
Data Services
Entertainment
Devices
FROM THE FOLLOWING:-
Wireless & Fixed Operators
Content Owners
Platform Owners
OS
Terminal & Platforms Vendors
OEM
ISP & MVNO’s
Handset Manufacturers
Satellite Operators
Content Retailers
Entertainment
Creative Agencies
Social Media
WHY SHOULD YOU ATTEND:-
3rd Annual Mobile Apps 2014 is the place to meet all the key decision makers across the mobile Application eco-system from enterprises, telecom operators, regulators, government agencies, service providers, system integrators, Developers and vendors. This congress will provide great networking opportunities with industry leaders, presenting you with the opportunity to meet and do business with like minded individuals.
8th Biosimilars Congregation 2016 conference which is taking place at 08th & 09th March 2016, The Kensington Close Hotel, Wrights Lane, London, UK.
For more details and registration simply email your interest and queries to Email – Deepak@virtueinsight.co.in
Best Regards,
Deepak Raj
Delegate and Sponsorship Sales
Virtue Insight
Gsm - + 91 9171350244
Tel - + 91 44 65515693
Skype - edeepakraj143
8th Biosimilars Congregation 2016 conference which is taking place at 08th & 09th March 2016, The Kensington Close Hotel, Wrights Lane, London, UK.
For more details and registration simply email your interest and queries to Email – Deepak@virtueinsight.co.in
Best Regards,
Deepak Raj
Delegate and Sponsorship Sales
Virtue Insight
Gsm - + 91 9171350244
Tel - + 91 44 65515693
Skype - edeepakraj143
Biosimilars or follow-on-biologics are the “copied” version of reference biologics, which are protected by intellectual rights that will expire soon. Patent expiration is the major driving factor of the biosimilars market. Most of the blockbuster patents will expire by the end of 2014, which would provide a competitive edge to local pharmaceutical manufacturers over the global players.
Greeting From Virtue Insight,
I am happy to invite you and your colleagues to be a sponsor/ delegate for our upcoming “9th Pharmacovigilance 2015” The conference will be held on 2nd September 2015, Kohinoor Continental Hotel, Mumbai, India.
KEY SPEAKERS:-
• V. Kalaiselvan, Principal Scientific Officer, Indian Pharmacopoeia Commission Ministry of Health and Family Welfare Govt. of India
• Arun Bhatt, President, ClinInvent Research
• Deepa Arora, Vice President - Pharmacovigilance & Global Head - Drug Safety & Risk Management, Lupin
• Bhaswat Chakraborty, Senior Vice President, Cadila
• Babita Kirodian, Head of Country Pharmacovigilance, Bristol Myers Squibb
• Nipom Deka, Regional Pharmacovigilance Manager, Asia, Africa & Middle East, Abbott
• Shashidhar Swamy, Head Pharmacovigilance, Wockhardt
• Mohammad Salim, Country Safety Lead, Pfizer
• Manish Verma, Director Medical Affairs, Sanofi
• Karthik Babu, Affiliate Pharmacovigilance Head, Sanofi
• Chirag Trivedi, Director & Head of Clinical Study Unit, Sanofi
• Priya Chatterjee, Director - Regulatory Affairs, Merck Serono
• Milind Antani, Partner In-Charge - Pharma LifeSciences, Nishith Desai Associate
• Anand Harugeri, Patient Safety and Regulatory Affairs Manager, Astrazeneca
• Deepti Sanghavi, Assistant Manager - Medical Writing, Tata Consultancy Services
• Sandeep Sewlikar, Manager – Clinical Affairs, Johnson and Johnson
• Girish Parhate, Head Regulatory Affairs, Bayer Pharmaceuticals
• Rajashri Survase Ojha, Founder and MD, Raaj GPRAC
• Vandana Jolad, Director, VIaTal Pharma
Plus Many More...
CONFERENCE BOOKING DETAILS:-
• Early Bird Discounted Price - Conference Delegate Pass (INR 6,000 + Tax (14%) per delegate) - Book and Pay before 20th July 2015 avail the early bird discounted price. You can simply email or call and book your conference delegate seats on TEL: +91 9940043915. Email – swetha@virtueinsight.co.in
• Standard Price after Early Bird Discounted Time – 1 or 2 Delegates (INR 7,000 + Tax (14%) per delegate) - You can simply email or call and book your conference delegate seats on TEL: +91 9940043915. Email – swetha@virtueinsight.co.in
• Group Discounts – 3 or 4 Delegates - (INR 6,500 + Tax (14%) per delegate)
• Group Discounts – 5 or more Delegates - (INR 5,000 + Tax (14%) per delegate)
• Conference Sponsor & Exhibition Stall - Should you wish to Sponsor, or purchase a Exhibition Stall (Booth) or a paid Speaker Slot, you can simply email your interest and queries to TEL: +91 44 65515695, +91 9940043915 or swetha@virtueinsight.co.in
In case you or any of your colleagues might be interested in participating in the same, please let me know and I will be happy to call you and help you with the registration.
Thank you for your time and consideration. I look forward to hearing from you
Thanks,
Swetha
Biosimilars or follow-on-biologics are highly similar versions of reference biologics derived from living organisms such as plants and animals. The development of biosimilars and validation with reference biologics play a significant role in the commercialization of biosimilars. Economic pricing of biosimilars, ease in development and a quick approval process are some key driving factors that drive the growth of this market. Effective and timely formulated regulations facilitate the viability and balance between original and biosimilar products. Moreover, a favorable regulatory environment and the establishment of IPR protections are factors that boost the market growth.
Greetings from Virtue Insight,
I am happy to invite you and your colleagues to be a sponsor/ delegate for our upcoming “9th Pharmacovigilance 2015” The conference will Be held on 2nd September 2015, Kohinoor Continental Hotel, Mumbai, India. Please find the detailed agenda for the same with this email.
FMD:- + 91 9171350244 or deepak@virtueinsight.co.in, deepakrajvirtueinsight@gmail.com
Pharma Policy 2017 - Read it in MedicinMan September 2017 IssueAnup Soans
1. Draft Pharma Policy: The Good, The Bad and The Ugly...............................................1
Interview with Sunil Attavar
2. Career Brand Plan: A Career Stepping
Stone..........................................................9
Soham Wagh
3. Succeeding as Country GM at GSK: A Whitepaper..............................................12
Sundar Ramachandran
4. Role of Digital in the Customer Journey ....................................................................21
Salil Kallianpur
5. Executive Function Disorder .................24
Vivek Hattangadi
applied strategic founder, Dr Richard Littlewood defined success factors for the next 10-year commercial phase of biosimilars at the 8th Biosimilars Congregation, held in London.
applied strategic founder, Dr Richard Littlewood defined success factors for the next 10-year commercial phase of biosimilars at the 8th Biosimilars Congregation, held in London.
Food Preservatives Market by Product Type, Distribution Channel, End User 202...IMARC Group
The global food preservatives market size reached US$ 3.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.3 Billion by 2032, exhibiting a growth rate (CAGR) of 3.8% during 2024-2032.
More Info:- https://www.imarcgroup.com/food-preservatives-market
Just to remind you that registrations for our 18th Pharmacovigilance 2019 event, which is taking place at The Pestana Chelsea Bridge Hotel in London, UK on 27-28th Feb are closing soon.For more details email to dinesh@virtueinsightsummits.com
Greetings from Virtue Insight,
I am happy to invite you and your colleagues to be a sponsor/ delegate for our upcoming “5th Pharmacovigilance Congregation 2013” The conference will be held on 20th November 2013, Kohinoor Continental Hotel, Mumbai, India.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
5th Biosimilars Congregation 2014
1. KEY SPEAKERS:-
Vimal Sanghavi, Vice President Clinical Trial Management,
Jim Thorn, EMEA Marketing and Applications Leader,
Martin Bluggel, CEO,
Pranjal Bordoloi, Senior General Manager – Late Phase Clinical Trials & Pharmacovigilance
Operations,
Pravin Ghadge, Head-Medical Writing & Pharmacovigilance,
Debolina Partap, AVP & Head Legal,
Siddarth S. Chachad, Head - Clinical Development,
Ashwani Pandita, Head Quality Management & Training,
Chirag Trivedi, Director & Head of Clinical Study Unit,
Manish Shah, General Manager, Global Clinical Operations,
Suresh Maroli, Head Clinical Pharmacology,
Sofi Joseph, Head – Regulatory Operations,
Yasmin Shenoy, Senior Director - Regulatory Affairs,
Milind Antani, Head - Pharma LifeSciences group,
Amey Mane, DGM-Medical Affairs,
V K Sharma, Associate Vice President,
Ambrish Srivastava, Asst Vice President,
Tej Krishen Bazaz, Director,
Lambda
SCIEX Separations (UK)
Protagen Protein Services (UK)
Lambda
Reliance Life Sciences
Wockhardt
Cipla
Glenmark
Sanofi
Wockhardt
Reliance Life Sciences
Pfizer
Sanofi
Nishith Desai Associates
Wockhardt
Unichem Laboratories
Alkem Labs
Thermo Fisher Scientific
Plus Many More...
Conference Hashtag - #VI_Pharma
2. ORGANIZED BY
ASSOCIATE PARTNER
SUPPORTED BY
5th Biosimilars Congregation 2014
10th September 2014, Kohinoor Continental Hotel, Mumbai, India
BRONZE PARTNER
SILVER PARTNER
SMS PARTNER
GOLD PARTNER
3. CONFERENCE INTRODUCTION:-
The biosimilar industry had a tough 2013 driven by the Indian economy having to experience one of its most turbulent times. Indian bio-pharma sector decelerated
to 5.2 per cent in 2013 from an average growth of 12 percent in the previous year. Adverse policy moves like the foreign direct investment (FDI), drug pricing,
clinical trials and compulsory licensing made the matters worse. An overactive US FDA hauled up several leading Indian pharma companies for non-compliance. All
these negative developments together turned 2013 into an 'Annus Horribilis’ for the Indian bio-pharma sector. The global biosimilars market is expected to be worth
$19.4 billion by 2014, growing at a Annual Growth Rate (CAGR) of 89.1% from 2009 to 2014.The American products Follow-on protein market (including North
America and Latin America) is expected to account for nearly 35.3% of the total income in 2014. By 2015, the sales of biosimilars is expected to hit USD 3.7bn, a
near exponential increase from USD 378 million back in 2011.
There are currently more than 80 biosimilars under development worldwide and this market could potentially become the only fastest-growing biologics sector by
2020. So, where did all this momentum come from? Why does biosimilars suddenly display an accelerated growth potential? And how have market dynamics
received and encouraged this growth? If Indian biopharmaceutical players are to compete effectively on the global scale and capture 10% of the global biosimilars
market by 2020, India’s private sector will have to invest a considerable amount of capital in building the necessary manufacturing capacity and skills base. At the
same time, the Government of India will also have to provide the necessary enabling environment. India’s biopharma sector consists primarily of monoclonal
antibodies, vaccines, recombinant proteins and diagnostics, and the guidelines for biosimilars are already in place.
Almost 50 biosimilars have already reached the Indian market, and they are sold at discounts of as much as 85%, putting them within reach of the masses. Demand
seems likely to grow considerably, as India becomes more affluent. US investment bank Goldman Sachs estimates that the number of Indians with annual incomes
of between $6,000 and $30,000 may increase by 250-300 million during the next decade alone. The global biosimilars market has even more potential for the most
efficient Indian biosimilars manufacturers, as the market will be characterised by price competition, even when there are only a less number of rival products. It is
said, the manufacturers of branded products are likely to use second-generation products with more convenient administration schedules as a means of defending
their territory. Few of these manufacturers may also try to crowd out the competition by producing their own biosimilars. So the competition is likely to be intense.
One of the most critical problem faced in India is the inaccessibility to healthcare. To address this issue, the government needs to not only relook at its public health
policy but also bring in various regulatory reforms including a smarter approval of pathway that cuts the cost of drug development to allow affordable innovations.
Regulatory reforms also need to address issues related to intellectual property and also clinical trials. Use of technology for procurement and distribution will also
enable better access to the drugs
This conference will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry.
Hence, this 5th Biosimilars Congregation 2014 will look at the multiple facets of biosimilars, ranging from the evolving regulatory landscape and challenges in clinical
development, to the legal and economic aspects. This Biosimilars conference will focus on multiple aspects of biosimilar product development to successfully deliver
safe, biosimilar products to the marketplace. By attending this conference you will gain a comprehensive outlook on the key issues surrounding biosimilars. This
event will provide an important platform for Biosimilars stakeholders to discuss and share best practices in expediting Biosimilars development.
It gives me great pleasure in welcoming all of you to the Virtue Insight’s 5th Biosimilars Congregation 2014. I wish and pray that all our efforts will be
beneficial to our industries folks at large.
WHY SHOULD YOU ATTEND:-
broader scope bringing the whole communications value chain together?
dedicated networking drinks time,meet the leading international vendors
Expand your knowledge
Get more from the event, with a Enjoy and make the best out
of our showcasing the products of tomorrow in the co-located
exhibition. of the latest business models and strategies in the high-level conference. Whether you are on the branded
or generic side, you cannot afford to miss this opportunity to benchmark your tactics and strategies against the industry leaders who will be the
first to traverse the pathway. Devise an immediate action plan for your biosimilar prosecution and litigation strategies in light of the barriers to
entry, research and development costs, and regulatory hurdles, which are balanced against an enormous potential for increased profit margin
KEY THEMES DISCUSSED AT THIS SUMMIT:-
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Commercialization and development strategies to gain a competitive advantage
Calculating possible revenue streams from biosimilar production
How should the pharma and generics industries approach the quickly emerging and developing biosimilar market?
What is the future of next generation Biosimilars?
The commercial challenges and opportunities to develop Biosimilars
The growing importance of biobetters over biosimilars
Gain in-depth knowledge on role of technology transfer - How does this affect market access?
How do policy makers shaping the contours of this new generic frontier, what implications they have for present biologic drug development & patent protection?
Next generation monoclonal antibody development and clinical challenges faced with biosimilar drug development
Technical case study for analytical and clinical comparability strategies
The Legal/IP for Biosimlars
How to maximise strategic partnerships to enter into the biosimlar market
New frontiers in cell line development and opportunities in biosimilars
How to reach the target audience more effectively and quickly.
Evaluating the key criteria that has to be considered to gain speedy entry into Biosimilar market
How global pharmaceutical market is turning to be more specialized & precise?
Identifying the experience on follow on biologics, generics and biosimilars has been so far
Gain up to date insight about the regulatory landscape and how it is effecting the industry
Boost your industry knowledge and relationships by networking and learning from key industry and academic leaders
WHO SHOULD ATTEND:-
CSOs, CMOs, Vice Presidents, Presidents, Heads, Directors, Team Leaders, and Senior Scientists from the following roles:
Biopharmaceuticals/ Biotherapeutics, Follow on Biologics/Follow on Proteins, Biologics/Biotechnology/ Biogenerics, Legal Affairs, Intellectual
Property, Health Economics, Pricing and Reimbursement, Clinical Immunology, Principal Scientist, Chief Scientific Officer, Process Control and
Analytical Technologies, Analytical Characterisation, Regulatory Compliance, Pharmacovigilance, Drug Safety & Risk Management, Quality Affairs/
Quality Control, New Product Development, Process Science, Portfolio Management, Research & Development, Business Development, Business
Operations, Scientific Affairs, Commercial Affairs
5th Biosimilars Congregation 2014
10th September 2014, Kohinoor Continental Hotel, Mumbai, India
4. Biosimilar Clinical Trials –
Challenges and Strategies
11:40 – Topic TBC
12:10 - Expanding the Role of Capillary Electrophoresis for the
Development, Characterization & Quality Control of Biologics
08:30 – Coffee and registration
09:30 – Chairpersons’s opening remarks
09:40 –
10:10 – Reaching and
demonstrating Biosimilarity by state of the art analytics
10:40 – Morning Coffee/Tea & Networking
• Regulatory demand for demonstrating biosimilarity
• Monitoring reference molecule
• Matching critical quality attributes during development
• Comparability exercise
V K Sharma, Associate Vice President,
Pranjal Bordoloi, Senior General Manager – Late Phase Clinical
Trials & Pharmacovigilance Operations,
Martin Bluggel, CEO,
Speaker TBC,
Jim Thorn, EMEA Marketing and Applications Leader,
Unichem Laboratories
Lambda
Protagen Protein Services (UK)
Medidata (UK)
SCIEX
Separations (UK)
(https://www.linkedin.com/pub/v-k-sharma/23/ba/197)
(https://www.linkedin.com/pub/martin-bl%C3%BCggel/2/891/89a)
(https://www.linkedin.com/pub/jim-thorn/9/361/428)
Morning Keynote Address 1:
Morning Keynote Address 2:
14:30 – Safety Evaluation in Biosimilars
15:00 – Clinical trials of Biosimilars: Challenges and
opportunities
15:30 – Afternoon Coffee/Tea & Networking
15:50 – Challenges in Patient Recruitment and Retention
• Regulatory aspects of a Biosimilar clinical trial
• Protocol development-Innovation in endpoints
• Challenges in the clinical operations
• Patient-centric approaches to increase patient recruitment
• Enhancing the site capabilities to improve the patient experience
• Social media and physicians involvement to improve patient
recruitment and retention
• Addressing the ‘weak link’ in medical research
Pravin Ghadge, Head - Medical Writing & Pharmacovigilance,
Amey Mane, DGM-Medical Affairs,
Reliance Life Sciences
Wockhardt
(http://www.linkedin.com/pub/dr-pravin-ghadge-
md/15/835/1a4)
(https://www.linkedin.com/pub/dr-amey-mane/6/156/7b1)
MARKET ANALYSIS
CHALLENGES & OPPORTUNITIES
13:50 - Panel Discussion: Strategies to Improve Sponsor, Site,
and CRO
Moderator:
Panellists:
• Overview of recent trends in clinical research
• Cultural considerations for a successful partnering
• Effective biosimilars clinical study designs for india
• Identifying the role of each stakeholder
Chirag Trivedi, Director & Head of Clinical Study Unit,
Tej Krishen Bazaz, Director,
Manish Shah, General Manager, Global Clinical Operations,
Ashwani Pandita, Head Quality Management & Training,
Sanofi
Thermo Fisher Scientific
Wockhardt
Glenmark
Lambda
(http://www.linkedin.com/pub/dr-chirag-trivedi/21/b0/344)
(http://www.linkedin.com/pub/dr-tej-krishen-bazaz/17/776/612)
(https://www.linkedin.com/pub/manish-shah/18/678/1a2)
(http://www.linkedin.com/pub/ashwani-pandita-rqap-
gcp/14/997/590)
(https://www.linkedin.com/pub/vimal-sanghavi/11/bb9/577)
Vimal Sanghavi, Vice President Clinical Trial Management,
5th Biosimilars Congregation 2014
10th September 2014, Kohinoor Continental Hotel, Mumbai, India
11:00 – Panel Discussion: Challenges And Opportunities For
Biosimilars In Emerging Markets
Moderator:
Panellists:
• Market size of biosimilars in the emerging market
• Selling of biosimilars in the emerging markets having government
protectionism
• Competition concentration of biosimilars in the emerging market
• Emerging markets that are highly attractive for biosimilars in india
Ambrish Srivastava, Asst Vice President,
Siddarth S. Chachad, Head - Clinical Development,
Suresh Maroli, Head Clinical Pharmacology,
Alkem Labs
Cipla
Reliance Life
Sciences
12:40 - Networking - Take your discussions
further & build new relationships in a relaxed
& informal setting...
luncheon
5. 17:00 – Chairperson’s closing remarks and end of conference
V K Sharma, Associate Vice President, Unichem Laboratories
(https://www.linkedin.com/pub/v-k-sharma/23/ba/197)
17:10 - 18:00 Networking Drinks - Take your discussions
further & build new relationships in a relaxed
& informal setting...
16:20 – Panel Discussion: Regulatory Updates and
Development
Moderator:
Panellists:
• Clinical approvals for biosimilars
• Regulatory differences between the DCGI, FDA, EMA and local
agencies in india and other emerging markets such as china & SEA
• How to demonstrate the process consistency and its requirements
• Updates on Biosimilars guidelines in indian market
• Regulatory demand for demonstrating biosimilarity
Milind Antani, Head-Pharma LifeSciences group,
Debolina Partap, AVP & Head Legal,
Yasmin Shenoy, Senior Director - Regulatory Affairs,
Sofi Joseph, Head–Regulatory Operations,
Nishith Desai
Associates
Wockhardt
Sanofi
Pfizer
(http://www.linkedin.com/pub/milind-antani/2/69a/5b5)
(http://www.linkedin.com/pub/debolina-partap/1b/388/424)
(http://www.linkedin.com/pub/sofi-joseph/12/307/632)
5th Biosimilars Congregation 2014
10th September 2014, Kohinoor Continental Hotel, Mumbai, India
REGULATORY
6. FLOOR PLAN:- Book your stalls now before they run out !!!
1
2 5
3
4
CONFERENCEHALL1
CONFERENCEHALL2
CONFERENCEHALL3
1
Coffee / Tea / Networking Area
POOL
SIDE AREA
NETWORKING
LUNCHEON
4
5 6
2
3
REGISTRATION
DESK
6
5th Biosimilars Congregation 2014
FLOOR PLAN - Book your stalls now before they run out !!!
7
7
7. Queries:
Payment terms:
Substitutions/name changes or cancellations:
Indemnity:
Fee:
How we will contact you:
Should you have any questions on bookings,
Please feel free to contact us.
Email:
Web:
India Office: Tel: +91 044 64536444
Virtue Insight requires the full amount to be paid before the
conference. Virtue Insight may refuse entry to delegates who have
not paid their invoice in full.
There is a 50% liability on all bookings once made, whether by post,
fax, or email. There is a no refund policy for cancellations received
on or after one month before the start of the event. Should you decide
to cancel after this date, the full invoice must be paid. Conference
notes will then be sent to you. Unfortunately, we are unable to transfer
places between conferences and executive briefings. However, if you
cannot attend the conference, you may make a substitution/name
change at any time, as long as we are informed in writing by email,
fax or post. Name changes and substitutions must be from the same
company or organization and are not transferable between countries.
Virtue Insight reserves the right to make alterations to the
conference/executive briefing content, timing, speakers or venue
without notice. The event may be postponed or cancelled due to
unforeseen events beyond the control of Virtue Insight. If such a
situation arises, we will refund your registration fee and we will try
to reschedule the event.
The conference fee includes lunch, refreshments and conference papers
provided on the day. This fee does not include travel or hotel
accommodation.
Virtue Insight's preferred method of communication is by email and
phone. Please ensure that you complete the registration form in full
so that we can contact you.
Kohinoor Continental Hotel
Andheri Kurla Road
Andheri ( E )
Mumbai 400059 - India
Tel: 91 22 66919000 / 91 22 28209999
General information Venue:
info@virtueinsight.com
http://www.virtueinsight.com
www.virtueinsight.com
News Updates:
Please tick if you do not wish to receive email updates in
the future
Registration Form
10th September 2014, Kohinoor Continental Hotel, Mumbai, India
Early Bird Discount Rate Till 28th July 2014
Standard Rate (From 29th July 2014)
Group Discounts
Group Discounts
Spot Registration:-
Methods of Payments:
By Bank Transfer:
1 Day conference per delegate - Fee: INR 5,000 + Tax
1 or 2 delegates - per delegate - Fee: INR 06,000 + Tax
3 or 4 delegates - per delegate - Fee: INR 05,500 + Tax
For 5 and above delegates - per delegate - Fee: INR 05,000 + Tax
1 Day conference per delegate - Fee: INR 07,000 + Tax
Forename ............................Surname ................................
Job Title ..............................Company ................................
Official Contact Number .......................................................
Address .............................................................................
.............................................................................
Country ...............................Postcode..................................
Phone ..................................Fax ........................................
Email .................................................................................
I confirm that I have read & agree to the
terms and conditions of booking..... (Please Tick)
Signature ...........................................................................
Complete and return the above registration form via
post or email, together with your cheque payable to Virtue Insight.
Virtue Insight
830092431
IDIB000V080
Indian Bank.
118 - 119, Indira Nagar, Valasaravakkam,
Chennai 600 087,Tiruvallur district,Tamil Nadu, India
By Cheque -
Account Name -
Account Number -
Sort code -
Bank Address -
Registration Form Details:
RESERVATION PRICING: